❓ Can a >30-month median progression-free survival redefine second-line HER2-positive metastatic breast cancer treatment? www.thelancet.com/journals/lan... 📰 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01)

🚨 GUARD International Symposium 2026 🚨 🔗 Register here: buff.ly/KGaHMZY Join us for a hybrid international meeting featuring both in-person attendance and live streaming, bringing together a multidisciplinary global faculty to discuss the latest advances in GU oncology. 📅 September 16–18, 2026

🚨 Can a single postoperative treatment meaningfully reduce recurrence after radical nephroureterectomy? The phase 3 JCOG1403 trial suggests the answer may be yes. www.thelancet.com/journals/lan...

Has the treatment paradigm for early relapsed multiple myeloma just shifted? Article👇 www.nejm.org/doi/full/10.... Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

FDA Approval🚨 Based on PSMAddition in #ProstateCancer Source: Novartis The FDA approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient pool. www.novartis.com/news/media-r...

🚨 GUARD International Symposium 2026 🚨 🔗 Register here: guardconsortium.org/actividad/gu... Join us for a hybrid international meeting featuring both in-person attendance and live streaming, bringing together a multidisciplinary global faculty to discuss the latest advances in GU oncology

Three landmark studies. One network meta-analysis. Which perioperative strategy currently shows the strongest signal for improving survival in muscle-invasive bladder cancer? Article👉 www.esmoopen.com/article/S205...

Are our clinical trials truly answering the questions that matter to the patients we treat every day? Article 👉 www.international-journal-of-gynecological-cancer.com/article/S104...

We warmly invite you to join @OncoAlert 🚨 in Lugano, Switzerland🇨🇭 , from April 29 to May 1, 2027, for #LPCCC27 — the Localized Prostate Cancer Consensus Conference. 👉 buff.ly/rgNSNqI 🔗 Register now and be part of #LPCCC27 in Lugano!

What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬 Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial www.nature.com/articles/s41...

Could the B cells within a tumour hold the blueprint for the next generation of cancer immunotherapies? Article👉 www.cell.com/cancer-cell/... Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies

📣 Call for Abstracts is OPEN! DEADLINE AUGUST 28, 2026 #IKCSNA26 Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America — taking place November 19–21, 2026, in Dallas, Texas. Transforming Kidney Cancer Research 🧬 appv2.sessionboard.com/submit/2026-...

🧬 Stay ahead of the latest in oncology with OncoAlert REGISTER Here 👉buff.ly/JJUzJh1 Cancer research is moving fast—and keeping up with the most relevant developments can be challenging.

Dear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments THERE ARE ONLY 1️⃣ 5️⃣ 0️⃣ SPOTS for FREE Registration (First Come First Seve REGISTER HERE 👉 buff.ly/I8wKRpo

The 5-year STELLAR trial results show that short-course radiotherapy☢️ followed by chemotherapy🧪 as total neoadjuvant therapy (TNT) offers a durable OS benefit Vs standard long-course chemoradiotherapy in locally advanced rectal cancer. Article 👉 buff.ly/ba1vWot

Can adding radium-223 to cabozantinib improve outcomes for patients with metastatic renal cell carcinoma and bone metastases? The RADICAL trial provides an important answer Article👉 ascopubs.org/doi/10.1200/... Radium-223 Dichloride & Cabozantinib in RCC W/ Bone Metastases: RADICAL

News From Industry: CLARITY-Gastric01 Update in gastric/GEJ cancers Source AstraZeneca Sone-Ve shows statistically significant & clinically meaningful OS benefit in the Phase III CLARITY-Gastric01 trial for patients w/ CLDN18.2-positive advanced gastric/GEJ cancers treated in the 2L and later

How much radiotherapy is enough—and can we personalize the dose without compromising patients’ quality of life? Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials www.thegreenjournal.com/article/S016...

ADCs 💊 are already changing cancer treatment—but are we getting the next generation right? Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

79.4% vs 66.2%: Could enfortumab vedotin plus pembrolizumab redefine perioperative treatment for bladder cancer? Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

We routinely prescribe anticancer therapies🧪 —but should we also be prescribing structured exercise 🏃‍♂️‍➡️ programs? Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial ascopubs.org/doi/full/10....

We warmly invite you to join @OncoAlert 🚨 in Lugano, Switzerland🇨🇭 , from April 29 to May 1, 2027, for #LPCCC27 — the Localized Prostate Cancer Consensus Conference. 👉 buff.ly/rgNSNqI 🔗 Register now and be part of #LPCCC27 in Lugano!

Could adding thoracic radiotherapy to immunotherapy in extensive-stage SCLC actually do more harm than good? The @OncoAlert 🚨 newsletter is Out GET IT HERE 👉 buff.ly/JJUzJh1

Could adding thoracic radiotherapy to immunotherapy in extensive-stage SCLC actually do more harm than good? Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Trial jamanetwork.com/journals/jam...

Join the 27th Annual International Lung Cancer Congress® for a high-impact update on lung cancer care, featuring the latest in immunotherapy, targeted therapy, ADCs, and multidisciplinary management. (HYBRID: OnLine & OnSite) 👉 REGISTER FREE with code OncoAlert. buff.ly/YnjTuRM July 24-25

The #WeekInOncology by @OncoAlert 🚨 Dr. Uğur Özkerim 🇹🇷 breaks down his top #LungCancer 🫁 picks: ELEVATE www.nejm.org/doi/full/10.... TREASURE jamanetwork.com/journals/jam... ARTEMIS-008 www.gsk.com/en-gb/media/...

Could a lung transplant become a treatment option for carefully selected patients with stage IV lung cancer? New data are challenging one of oncology’s long-standing assumptions. Lung Transplant for Refractory Lung-Limited Stage IV Non–Small Cell Lung Cancer jamanetwork.com/journals/jam...

Childhood Cancer Survival Outcomes in India: A Scoping Review of Three Decades of Survival Data for Policy Insights ascopubs.org/doi/10.1200/... Childhood cancer survival in India🇮🇳 remains poorly documented despite a high disease burden.

Does deeper HIF-2α suppression mean better outcomes in Refractory Clear Cell #KidneyCancer? We are here with another #WeekInOncology and no other than our faculty Natalia Gandur from Argentina🇦🇷 to guide us through this great publication

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis jamanetwork.com/journals/jam... Supporting the reliability of investigator-assessed outcomes in these trials.